Arialys Therapeutics
$14.0M
Funding date
Valuation / Funding
No funding history available
Funding data has not been imported for this company yet
Current Valuation Metrics
Arialys Therapeutics is currently valued at $112.0M as of June 30, 2025. The company has raised a total of $72.0M in funding.
Capital Efficiency
With a capital efficiency ratio of 1.56x, Arialys Therapeutics has achieved a valuation that is 1.56 times the total capital raised. This metric indicates room for improvement in capital deployment.
Investment Perspective
Arialys Therapeutics's valuation reflects investor confidence in the company's market position, growth potential, and ability to execute on its business model. Private market valuations are determined by primary funding rounds and secondary market transactions, which take into account financial performance, market conditions, and growth prospects.
What is Arialys Therapeutics Worth in 2025?
As of 2025, Arialys Therapeutics is valued at $112.0M, based on the company's Seed Round funding round in June 30, 2025. This valuation positions Arialys Therapeutics as one of the leading private companies in the sector.
Arialys Therapeutics Valuation History
Arialys Therapeutics's funding history demonstrates steady growth and investor confidence.
How Arialys Therapeutics Valuation is Determined
Private company valuations like Arialys Therapeutics's are determined through primary funding rounds led by venture capital firms, private equity investors, and strategic partners. The valuation reflects factors including:
- Revenue growth and financial performance
- Market opportunity and total addressable market (TAM)
- Competitive positioning and market share
- Management team strength and execution capability
- Technology and intellectual property
- Industry trends and investor sentiment
Arialys Therapeutics Valuation FAQs
Is Arialys Therapeutics profitable?
Arialys Therapeutics has not publicly disclosed its profitability status. Many high-growth private companies prioritize market expansion and user growth over profitability in their early stages.
How does Arialys Therapeutics's valuation compare to competitors?
Arialys Therapeutics is valued at $112.0M, positioning it as a major player in the space. Secondary market pricing and private market transactions provide ongoing validation of this valuation.
When will Arialys Therapeutics IPO?
Arialys Therapeutics has not announced plans for an initial public offering. Until an IPO, investors can access Arialys Therapeutics shares through secondary market platforms.